TMDX (TransMedics Group) Dividends Paid

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TMDX TransMedics Group Inc TMDX
74 GF Score
Price $88.26
GF Value $158.79
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is TransMedics Group Dividends Paid?

Dividends Paid only applicable to companies reporting Cash Flow from Operations in direct method.

TMDX
74GF Score
TransMedics Group Inc TMDX
Dividends Paid is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is TransMedics Group (TMDX) Overvalued in 2026?

Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued. The current stock price of $88.26 is trading 44.4% below its estimated GF Value™ of $158.79. GuruFocus considers TransMedics Group to be Possible Value Trap.

Key valuation signals for TMDX:

  • Dividends Paid:
  • GF Value™: $158.79 vs. price of $88.26 (44.4% below fair value)
  • GF Score™: 74/100 with 9 warning signs

No single metric tells the full story. See the TMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TransMedics Group Business Description

Address 200 Minuteman Road, Andover, MA, USA, 01810
TransMedics Group Inc. is a commercial-stage medical technology company focused on organ transplant therapy for patients with end-stage organ failure. Its core product is the Organ Care System (OCS), a portable perfusion, optimization, and monitoring platform that maintains donor organs in a near-physiologic state outside the body, addressing limitations of traditional cold storage. The company offers OCS systems for heart, lung, and liver transplantation, and also provides a national organ transportation and logistics service through its TransMedics Organ Care System network. Customers include transplant centers, hospitals, and organ procurement organizations, primarily in the United States, with additional markets in Europe and other regions. Revenue is generated through sales of OCS consoles, disposable perfusion sets, and related services, including its organ transport offering, which together support its commercial expansion in the transplant market.
74GF Score

Get the complete analysis for TMDX

Dividends Paid is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$88.26
Price
$158.79
GF Value